Literature DB >> 19285954

Tumorigenic properties of alternative osteopontin isoforms in mesothelioma.

Sergey V Ivanov1, Alla V Ivanova, Chandra M V Goparaju, Yuanbin Chen, Amanda Beck, Harvey I Pass.   

Abstract

Osteopontin (SPP1) is an inflammatory cytokine that we previously characterized as a diagnostic marker in patients with asbestos-induced malignant mesothelioma (MM). While SPP1 shows both pro- and anti-tumorigenic biological effects, little is known about the molecular basis of these activities. In this study, we demonstrate that while healthy pleura possesses all three differentially spliced SPP1 isoforms (A-C), in clinical MM specimens isoform A is markedly up-regulated and predominant. To provide a clue to possible functions of the SPP1 isoforms we next performed their functional evaluation via transient expression in MM cell lines. As a result, we report that isoforms A-C demonstrate different activities in cell proliferation, wound closure, and invasion assays. These findings suggest different functions for SPP1 isoforms and underline pro-tumorigenic properties of isoforms A and B.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285954     DOI: 10.1016/j.bbrc.2009.03.042

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 2.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

Review 3.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 4.  Lung cancer cell lines as tools for biomedical discovery and research.

Authors:  Adi F Gazdar; Luc Girard; William W Lockwood; Wan L Lam; John D Minna
Journal:  J Natl Cancer Inst       Date:  2010-08-02       Impact factor: 13.506

Review 5.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

6.  The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.

Authors:  Donald Courter; Hongbin Cao; Shirley Kwok; Christina Kong; Alice Banh; Peiwen Kuo; Donna M Bouley; Carmen Vice; Odd Terje Brustugun; Nicholas C Denko; Albert C Koong; Amato Giaccia; Quynh-Thu Le
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

7.  Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Authors:  K D M Nakamura; T M Tilli; J L Wanderley; A Palumbo; R M Mattos; A C Ferreira; C E Klumb; L E Nasciutti; E R Gimba
Journal:  Tumour Biol       Date:  2015-09-24

8.  Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study.

Authors:  Giuseppe Mastrangelo; Gianluca Marangi; Maria N Ballarin; Silvia Michilin; Aline S C Fabricio; Flavio Valentini; John H Lange; Ugo Fedeli; Luca Cegolon; Massimo Gion
Journal:  BMC Public Health       Date:  2011-04-08       Impact factor: 3.295

9.  Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.

Authors:  Antje Hahnel; Henri Wichmann; Thomas Greither; Matthias Kappler; Peter Würl; Matthias Kotzsch; Helge Taubert; Dirk Vordermark; Matthias Bache
Journal:  BMC Cancer       Date:  2012-04-02       Impact factor: 4.430

10.  Phenotypes and karyotypes of human malignant mesothelioma cell lines.

Authors:  Vandana Relan; Leanne Morrison; Kylie Parsonson; Belinda E Clarke; Edwina E Duhig; Morgan N Windsor; Kevin S Matar; Rishendran Naidoo; Linda Passmore; Elizabeth McCaul; Deborah Courtney; Ian A Yang; Kwun M Fong; Rayleen V Bowman
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.